21 – 40 of 304
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism
(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers
(
- Contribution to journal › Article
-
Mark
REST suppression mediates neural conversion of adult human fibroblasts via microRNA-dependent and -independent pathways
(
- Contribution to journal › Article
-
Mark
Preclinical effects of APOE ϵ4 on cerebrospinal fluid Aβ42 concentrations
(
- Contribution to journal › Article
-
Mark
Levels of cerebrospinal fluid biomarkers total tau and phosphorylated tau do not predict survival time after diagnosis of Alzheimer’s disease – An 18-year follow-up.
2017) 10th Clinical Trials Conference on Alzheimer’s Disease(
- Contribution to conference › Poster
-
Mark
The Montreal Cognitive Assessment : Normative Data from a Large Swedish Population-Based Cohort
(
- Contribution to journal › Article
-
Mark
No independent association between pulse wave velocity and dementia : a population-based, prospective study
(
- Contribution to journal › Article
-
Mark
The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Importance and added value of functional impairment to predict mortality : A cohort study in Swedish medical inpatients
(
- Contribution to journal › Article
-
Mark
The course and end-points of Alzheimer’s disease according to sociodemographics, apolipoprotein E genotype and cognitive ability.
2017) Alzheimer's Association International Conference (AAIC), 2017(
- Contribution to conference › Poster
-
Mark
The outcomes of different assessment scales can predict survival in patients with Alzheimer’s disease
2017) 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2017) In Neurodegenerative Diseases 17(Suppl. 1). p.27-27(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
(
- Contribution to journal › Article
-
Mark
Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis.
(
- Contribution to journal › Article
-
Mark
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios : better diagnostic markers of Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio – a cross-validation study against amyloid PET
(
- Contribution to journal › Article
-
Mark
Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Cholinesterase inhibitor therapy does not affect time spent in nursing homes in patients with Alzheimer’s disease.
2016) Alzheimer’s Association International Conference 2016(
- Contribution to conference › Poster
-
Mark
A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease : A prospective, observational study of factors affecting survival time from admission to death.
(
- Contribution to journal › Article
-
Mark
Copeptin, a Marker of Vasopressin, Predicts Vascular Dementia but not Alzheimer's Disease
(
- Contribution to journal › Article